Loading…

Antioxidants cause rapid expansion of human adipose-derived mesenchymal stem cells via CDK and CDK inhibitor regulation

Antioxidants have been shown to enhance the proliferation of adipose-derived mesenchymal stem cells (ADMSCs) in vitro, although the detailed mechanism(s) and potential side effects are not fully understood. During log-phase growth, exposure to ImF-A resulted in a higher percentage of ADMSCs in the S...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biomedical science 2013-08, Vol.20 (1), p.53-53, Article 53
Main Authors: Sun, Li-Yi, Pang, Cheng-Yoong, Li, Dian-Kun, Liao, Chia-Hsin, Huang, Wei-Chao, Wu, Chao-Chuan, Chou, Yi-Yo, Li, Wei Wu, Chen, Shin-Yuan, Liu, Hwan-Wun, Chang, Yao-Jen, Cheng, Ching-Feng
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antioxidants have been shown to enhance the proliferation of adipose-derived mesenchymal stem cells (ADMSCs) in vitro, although the detailed mechanism(s) and potential side effects are not fully understood. During log-phase growth, exposure to ImF-A resulted in a higher percentage of ADMSCs in the S phase of the cell cycle and a smaller percentage in G0/G1 phase. This resulted in a significantly reduced cell-doubling time and increased number of cells in the antioxidant-supplemented cultures compared with those supplemented with FGF-2 alone, an approximately 225% higher cell density after 7 days. Western blotting showed that the levels of the CDK inhibitors p21 and p27 decreased after ImF-A treatment, whereas CDK2, CDK4, and CDC2 levels clearly increased. In addition, ImF-A resulted in significant reduction in the expression of CD29, CD90, and CD105, whereas relative telomere length, osteogenesis, adipogenesis, and chondrogenesis were enhanced. The results were similar for ADMSCs treated with antioxidants and those under hypoxic conditions. Antioxidant treatment promotes entry of ADMSCs into the S phase by suppressing cyclin-dependent kinase inhibitors and results in rapid cell proliferation similar to that observed under hypoxic conditions.
ISSN:1423-0127
1021-7770
1423-0127
DOI:10.1186/1423-0127-20-53